
|Articles|November 26, 2012
FDA panel votes against OTC use of OAB agent
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Regimen: Pharmacists Bridging the Treatment Gap for Patients with OUD
2
Q&A: Expert States Loudest Medical Content on Social Media Is Typically Negative
3
Community Pharmacies Face Barriers Amid PBM Practices, Industry Shifts
4
Evoke Trials Show No Alzheimer Reduction Among Semaglutide Users
5





































































































































